Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF -2.01%82 Return-on-Tangible-Asset is 7.42% as of Dec. 2025, which is 21% below its 10-year median of 9.37. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.54 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 75.5% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hikma Pharmaceuticals's annualizedNet Income for the quarter that ended in Dec. 2025 was $328 Mil. Hikma Pharmaceuticals's average total tangible assets for the quarter that ended in Dec. 2025 was $4,419 Mil. Therefore, Hikma Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 7.42%.
The historical rank and industry rank for Hikma Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
HKMPF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -30.98 Med: 9.37 Max: 16.41
Current: 9.21
During the past 13 years, Hikma Pharmaceuticals's highest Return-on-Tangible-Asset was 16.41%. The lowest was -30.98%. And the median was 9.37%.
HKMPF's Return-on-Tangible-Asset is ranked better than 75.5% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.155
vs HKMPF: 9.21
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hikma Pharmaceuticals Return-on-Tangible-Asset Related Terms
Hikma Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.42% mean?
Hikma Pharmaceuticals (HKMPF) has a Return-on-Tangible-Asset of 7.42% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hikma Pharmaceuticals and its competitors. This is 21% below median its historical median of 9.37. According to the industry distribution chart, Hikma Pharmaceuticals ranks #247 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Hikma Pharmaceuticals' Return-on-Tangible-Asset too high?
Hikma Pharmaceuticals' current Return-on-Tangible-Asset of 7.42% is 21% below median its 10-year median of 9.37. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Hikma Pharmaceuticals' value of 7.42% is 135.2% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #247 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #247 out of 1008 companies for Return-on-Tangible-Asset. This places Hikma Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. Hikma Pharmaceuticals' value of 7.42% is 135.2% above this benchmark. While the company's 10-year median is 9.37 vs. the industry median of 3.16, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Return-on-Tangible-Asset of 7.42% is 135.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Return-on-Tangible-Asset is 7.42%, which is 21% below median its own 10-year median of 9.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.54, compared to a current price of $21.26 — trading 25.5% below its estimated fair value. The current Return-on-Tangible-Asset is 7.42%, which is 21% below median its 10-year median of 9.37 and 135.2% above the Drug Manufacturers industry median of 3.16. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Return-on-Tangible-Asset is 7.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.54.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Return-on-Tangible-Asset: 7.42% (21% below median its 10-year median of 9.37)
GF Value™: $28.54 vs. price of $21.26 (25.5% below fair value)
Industry Position: 135.2% above the Drug Manufacturers median (#247 of 1008)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
